Table 1. Clinical and demographic characteristics of the study population in relation to 3-month outcomes.
Characteristics | Good outcome (n = 925) | Poor outcome (n = 165) | P Value |
---|---|---|---|
Age, y | 59.32 ± 12.64 | 64.13 ± 12.21 | 0.001 |
Male | 636 (68.8%) | 102 (61.8%) | 0.037 |
Smoking | 315 (34.5%) | 67 (41.1%) | 0.018 |
Statin use history | 51 (5.5%) | 15 (9.1%) | 0.034 |
NIHSS score at admission | 3 (2–5) | 8 (4–12) | < 0.001 |
Hypertension | 539 (58.3%) | 109 (65.8%) | 0.059 |
CHD | 99 (10.8%) | 29 (17.2%) | 0.013 |
Atrial fibrillation | 41 (4.5%) | 19 (11.5%) | 0.004 |
Diabetes mellitus | 182 (19.7%) | 43 (25.8%) | 0.057 |
Stroke | 192 (20.9%) | 51 (30.1%) | 0.007 |
Dyslipidemia | 97 (10.4%) | 17 (10.2%) | 0.949 |
WBC, 109/L | 7.21 (5.91–8.41) | 7.61 (6.43–8.71) | 0.062 |
Neutrophil, 109/L | 4.93 (3.62–5.71) | 5.21 (4.02–6.69) | 0.017 |
Lymphocyte, 109/L | 1.73 (1.41–2.14) | 1.71 (1.11–1.97) | 0.059 |
MONO, 109/L | 0.51 (0.41–0.63) | 0.55 (0.43–0.67) | 0.027 |
CHO, mmol/L | 4.19 (3.49–4.87) | 4.15 (3.47–4.99) | 0.695 |
TG, mmol/L | 1.35 (0.95–1.84) | 1.12 (0.88–1.70) | 0.012 |
LDL-C, mmol/L | 2.67 (2.10–3.24) | 2.55 (1.92–3.26) | 0.280 |
HDL-C, mmol/L | 1.09 (0.93–1.29) | 1.03 (0.89–1.22) | 0.036 |
MHR | 0.48 (0.33–0.60) | 0.53 (0.37–0.69) | 0.007 |
NIHSS, National Institutes of Health Stroke Scale; CHD, coronary heart disease; WBC, white blood cell, MONO, monocyte; CHO, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein and MHR, monocyte to high-density lipoprotein ratio.